. Which the company will sign the share purchase agreement on July 24, 2019. Details of such items appear in Attachment 1: Information Memorandum Concerning the Disposition of Assets Please be informed
expenses 71.35 64.90 6.45 9.94% Net profit 344.32 305.36 38.96 12.76% Net profit attributable to owner of the parent 341.71 302.67 39.04 12.90% Earnings per share (EPS) 0.21 0.18 0.02 12.90% Note: 1) Revenue
improved following on-going cost optimization and FY17 guidance maintained. AIS reported 3Q17 EBITDA of Bt17,589mn, +15% YoY and +2.8% QoQ, mainly due to revenue growth and controlled SG&A. YTD, AIS spent
processes, including effectively controlled in maintenance cost. Net gain (loss) on exchange rate Q1-2020 Q1-2019 THB Mn THB Mn THB Mn % Net gain (loss) on exchange rate 112.2 (28.3) 140.5 N.A. (>100) Change
debt obligations. 2. Disclosure of compensation a. Issuer’s directors are on an individual basis; and b. Issuer’s senior managements are on lump sum basis. C. Share Ownership Provide current information
be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the
decreased by -8.4% YoY. 9M23 EBITDA increased by 4.2% YoY as a result of an improvement in core service revenue and well- controlled SG&A. The net profit closed at Bt22,084mn, surging 18% YoY driven by